Harrow

Q2 FY2026 EarningsQ2 FY26 results presented a mix of top-line strength and bottom-line pressure: revenue reached $70.7M, slightly beating the $70.4M consensus, driven by a 40% sequential surge in VEVYE sales. However, gross margin fell short at 71.0% vs. 75.3% expected, and GAAP EPS of -$0.46 significantly missed the -$0.18 mean estimate due to elevated SG&A and R&D spending associated with portfolio expansion. Management reiterated FY26 revenue guidance of $350M–$365M, suggesting a significant hockey-stick growth requirement in H2 FY26.